<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705454</url>
  </required_header>
  <id_info>
    <org_study_id>ADCT-402 EAP</org_study_id>
    <nct_id>NCT04705454</nct_id>
  </id_info>
  <brief_title>Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADC Therapeutics S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ADC Therapeutics S.A.</source>
  <brief_summary>
    <textblock>
      The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL)&#xD;
      that cannot be treated by currently available drugs, cell therapy, or clinical trials. ADC&#xD;
      Therapeutics will evaluate patients for approval into the program.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Loncastuximab Tesirine</intervention_name>
    <other_name>Zynlonta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient aged 18 years or older&#xD;
&#xD;
          -  Pathologic diagnosis of DLBCL&#xD;
&#xD;
          -  Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) that cannot be treated&#xD;
             by currently available drugs, cell therapy, or clinical trials&#xD;
&#xD;
          -  Women of childbearing potential must agree to use a highly effective method of&#xD;
             contraception from the time of giving informed consent until at least six months after&#xD;
             the last dose of loncastuximab tesirine. Men with female partners who are of&#xD;
             childbearing potential must agree that they will use a highly effective method of&#xD;
             contraception from the time of giving informed consent until at least six months after&#xD;
             the patient receives his last dose of loncastuximab tesirine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of hypersensitivity to or positive serum human Anti-Drug Antibodies to&#xD;
             loncastuximab tesirine&#xD;
&#xD;
          -  Total bilirubin &gt;1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic&#xD;
             prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the&#xD;
             breast, or other malignancy that ADCT Head of Medical Affairs and/or designee, and&#xD;
             treating physician agree and document should not be exclusionary&#xD;
&#xD;
          -  Autologous Stem Cell Transplantation (SCT) within 30 days prior to start of&#xD;
             loncastuximab tesirine&#xD;
&#xD;
          -  Allogeneic SCT within 60 days prior to start of loncastuximab tesirine&#xD;
&#xD;
          -  Clinically significant third space fluid accumulation (i.e., ascites requiring&#xD;
             drainage or pleural effusion that is either requiring drainage or associated with&#xD;
             shortness of breath)&#xD;
&#xD;
          -  Lymphoma with active central nervous system involvement at the time of screening,&#xD;
             including leptomeningeal disease&#xD;
&#xD;
          -  Breastfeeding or pregnant&#xD;
&#xD;
          -  Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14&#xD;
             days prior to starting loncastuximab tesirine, except shorter if approved by ADCT&#xD;
&#xD;
          -  Use of any other experimental medication within 14 days prior to starting&#xD;
             loncastuximab tesirine&#xD;
&#xD;
          -  Any other significant medical illness, abnormality, or condition that would, in the&#xD;
             treating physician's judgment, make the patient inappropriate to receive loncastuximab&#xD;
             tesirine or put the patient at risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Expanded Access</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Large B-Cell</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loncastuximab tesirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

